$301 Million is the total value of CHI Advisors LLC's 20 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Buy | CULLINAN ONCOLOGY INC | $38,215,000 | -24.6% | 2,476,720 | +10.3% | 12.68% | -14.2% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $34,688,000 | -17.3% | 2,569,479 | +3.4% | 11.51% | -6.0% |
| VECT | Buy | VECTIVBIO HLDG AG | $13,136,000 | -34.4% | 2,675,408 | +3.2% | 4.36% | -25.4% |
| ONCR | Buy | ONCORUS INC | $11,104,000 | -32.3% | 2,106,903 | +20.0% | 3.69% | -23.0% |
| IKNA | Buy | IKENA ONCOLOGY INC | $10,217,000 | +157.0% | 814,756 | +158.7% | 3.39% | +192.3% |
| CMPX | New | COMPASS THERAPEUTICS INC | $9,585,000 | – | 3,023,692 | +100.0% | 3.18% | – |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $8,514,000 | -9.3% | 6,449,856 | +58.0% | 2.83% | +3.1% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $4,552,000 | +602.5% | 272,250 | +263.0% | 1.51% | +699.5% |
| FRLN | Buy | FREELINE THERAPEUTICS HLDGSsponsored ads | $3,715,000 | -23.7% | 1,876,389 | +31.4% | 1.23% | -13.2% |
| GTHX | Buy | G1 THERAPEUTICS INC | $2,348,000 | +249.9% | 230,000 | +360.0% | 0.78% | +297.4% |
| OVID | Buy | OVID THERAPEUTICS INC | $1,284,000 | +63.6% | 400,000 | +71.3% | 0.43% | +86.0% |
| KROS | Buy | KEROS THERAPEUTICS INC | $1,025,000 | +105.0% | 17,518 | +38.7% | 0.34% | +132.9% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $964,000 | +20.0% | 400,000 | +141.1% | 0.32% | +36.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.